Cochlear Resultados de beneficios anteriores

Pasado controles de criterios 5/6

Cochlear ha aumentado sus ingresos a un ritmo medio anual de 14.3%, mientras que la industria Medical Equipment ha visto aumentar sus ingresos growing a 7.2% anualmente. Los ingresos han crecido growing a un ritmo medio anual de 8.3%. Cochlear La rentabilidad de los fondos propios de la empresa es de 19.7% y sus márgenes netos son de 16.3%.

Información clave

14.3%

Tasa de crecimiento de los beneficios

10.8%

Tasa de crecimiento del BPA

Crecimiento de la industria Medical Equipment	5.8%
Tasa de crecimiento de los ingresos	8.3%
Rentabilidad financiera	19.7%
Margen neto	16.3%
Próxima actualización de resultados	15 Aug 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Cochlear. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

CHIA:COH Ingresos, gastos y beneficios (AUD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	2,149	350	874	270
30 Sep 23	2,043	326	842	257
30 Jun 23	1,936	301	810	245
31 Mar 23	1,824	281	768	230
31 Dec 22	1,713	261	725	215
30 Sep 22	1,681	275	691	213
30 Jun 22	1,648	289	658	211
31 Mar 22	1,612	273	628	208
31 Dec 21	1,575	257	597	205
30 Sep 21	1,536	291	579	200
30 Jun 21	1,498	324	560	195
31 Mar 21	1,403	82	549	187
31 Dec 20	1,308	-160	537	180
30 Sep 20	1,314	-199	550	182
30 Jun 20	1,321	-238	564	185
31 Mar 20	1,400	34	569	188
31 Dec 19	1,479	306	574	190
30 Sep 19	1,453	291	560	187
30 Jun 19	1,427	277	546	184
31 Mar 19	1,422	270	535	180
31 Dec 18	1,418	264	525	175
30 Sep 18	1,391	255	510	172
30 Jun 18	1,364	246	494	168
31 Mar 18	1,329	234	475	164
31 Dec 17	1,294	223	456	160
30 Sep 17	1,274	223	444	156
30 Jun 17	1,254	224	432	152
31 Mar 17	1,218	215	426	149
31 Dec 16	1,182	206	420	146
30 Sep 16	1,156	198	412	146
30 Jun 16	1,131	189	403	145
31 Mar 16	1,088	179	383	142
31 Dec 15	1,045	168	362	138
30 Sep 15	986	157	341	133
30 Jun 15	926	146	320	128
31 Mar 15	899	145	308	126
31 Dec 14	872	144	296	124
30 Sep 14	839	119	288	126
30 Jun 14	805	94	279	128
31 Mar 14	769	85	267	129
31 Dec 13	732	76	256	130
30 Sep 13	742	104	248	127
30 Jun 13	753	133	241	125

Ingresos de calidad: COH tiene ganancias de alta calidad.

Margen de beneficios creciente: COHLos actuales márgenes de beneficio netos de (16.3%) son superiores a los del año pasado (15.3%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: COHLos beneficios de la empresa han crecido un 14.3% al año en los últimos 5 años.

Acelerando crecimiento: COHEl crecimiento de los beneficios de la empresa en el último año (34%) supera su media de 5 años (14.3% al año).

Beneficios vs. Industria: COH El crecimiento de los beneficios en el último año (34%) superó al del sector Medical Equipment -3% .

Rentabilidad financiera

Alto ROE: El Retorno sobre el capital de COH (19.7%) se considera bajo.

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Cochlear Resultados de beneficios anteriores

Pasado controles de criterios 5/6

Información clave

Actualizaciones de resultados anteriores recientes

First half 2024 earnings released: EPS: AU$2.92 (vs AU$2.15 in 1H 2023)

Cochlear Limited to Report Fiscal Year 2024 Results on Aug 15, 2024

Full year 2023 earnings released: EPS: AU$4.57 (vs AU$4.40 in FY 2022)

Full year 2022 earnings released: EPS: AU$4.40 (vs AU$4.93 in FY 2021)

Cochlear Limited to Report First Half, 2023 Results on Feb 15, 2023

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

Recent updates

Upcoming dividend of AU$2.00 per share

First half 2024 earnings released: EPS: AU$2.92 (vs AU$2.15 in 1H 2023)

Upcoming dividend of AU$1.75 per share at 1.2% yield

Cochlear Limited Introduces Next Generation Cochlear Osia System with Ability to Have MRI at 3.0 T

Cochlear Limited to Report Fiscal Year 2024 Results on Aug 15, 2024

Full year 2023 earnings released: EPS: AU$4.57 (vs AU$4.40 in FY 2022)

Cochlear Limited Announces Andrew Denver, Non-Executive Director Intention to Retire At AGM to Be Held on 17 October 2023

Upcoming dividend of AU$1.55 per share at 1.3% yield

Cochlear Limited Provides Earnings Outlook for the Year 2023

Cochlear Limited (ASX:COH) announces an Equity Buyback for AUD 75 million worth of its shares.

Cochlear Limited, Annual General Meeting, Oct 17, 2023

FDA Approves Cochlear Limited's Nucleus 8 Sound Processor, Smaller, Smarter, Better Connected Cochlear Implant Technology

Key Executive recently bought AU$97k worth of stock

Upcoming dividend of AU$1.45 per share

Full year 2022 earnings released: EPS: AU$4.40 (vs AU$4.93 in FY 2021)

Cochlear Announces Final Dividend Payable on 17 October 2022

Cochlear Limited Appoints Karen Penrose to Board, Effective on 1 July 2022

Cochlear Limited, Annual General Meeting, Oct 18, 2022

Cochlear Limited to Report First Half, 2023 Results on Feb 15, 2023

Upcoming dividend of AU$1.55 per share

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

Cochlear Limited Announces Interim Dividend Expected to Be Payable on 21 April 2022

FDA Approves Cochlear Nucleus Implants for Unilateral Hearing Loss/Single-Sided Deafness

Independent Non-Executive Director recently bought AU$56k worth of stock

Cochlear Limited Advises of US Patent Infringement Complaint

Upcoming dividend of AU$1.40 per share

Sensorion and Cochlear to Begin First Clinical Trial of SENS-401 for Hearing Preservation in Combination with Cochlear Implantation

Independent Non-Executive Director recently bought AU$94k worth of stock

Independent Chairman Roderic Holliday-Smith has left the company

Full year 2021 earnings released: EPS AU$4.97 (vs AU$4.00 loss in FY 2020)

Cochlear Limited Provides Earnings Guidance for the Fiscal Year 2022

Non-Executive Independent Director Abbas Hussain has left the company

New Cochlear CoPilot app to help adults improve hearing outcomes through skills training

Upcoming Dividend of AU$1.15 Per Share

Cochlear Receives FDA Clearance of Baha 6 Max, Industry's Smallest 55 dB Sound Processor Now with Direct Android Streaming

Independent Non-Executive Director recently bought AU$164k worth of stock

Cochlear Limited Receives US Food and Drug Administration Approval for Baha 6 Max Sound Processor

First half 2021 earnings released: EPS AU$3.59 (vs AU$2.73 in 1H 2020)

Revenue beats expectations

Cochlear Limited Appoints Stu Sayers as Chief Financial Officer

New 90-day low: AU$189

New 90-day low: AU$194

Cochlear Limited Appoints Stu Sayers as Acting CFO

New 90-day high: AU$233

Cochlear Limited Appoints Stephen Mayne as Director

Cochlear Limited to Report Fiscal Year 2021 Results on Aug 20, 2021

Cochlear Limited to Report Fiscal Year 2020 Results on Aug 18, 2020

Desglose de ingresos y gastosBeta

Historial de beneficios e ingresos

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Rentabilidad financiera

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Desglose de ingresos y gastos
Beta